Anteo Diagnostics specialises in the development and commercialisation of proprietary surface coatings for applications in the diagnostics and biotech industries. With Mix&Go we have developed ?molecular glues? which are used by our partners and customers to immobilize delicate biological molecules such as antibodies to synthetic surfaces.
The company develops biomedical nanoparticle technology and products for research and treatment of human disease. They are developing NanoElectroPlex™, a proprietary tissue selective nanoparticle platform technology based on biodegradable macromolecular carriers.
ApoLife has developed platform yeast expression technologies for accelerated development of therapeutic antibodies (glycosylated and aglycosylated), antibody fragments, fusion proteins and next generation antibodies and subunit vaccines through its proprietary Twin Cassette yeast system.
Arrayit Corporation empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.
AuraSense's uniquely engineered nanoparticles possess unparalleled biocompatibility and versatility as therapeutics and as novel assays within live cells. They hold great promise for combating the most threatening diseases, including heart disease, cancer, and bacterial infection.
The company is a service partner for all aspects of oligonucleotides. It developed and produced the world's first and only translucent orthodontic systems using novel nanotechnology polymer composite products.
Celsense is a biotechnology company offering novel MRI contrast agents (fluorochemical nanoparticles) that allow scientists and clinicians to monitor the position and quantity of transplanted cells non-invasively in vivo.
The company develops and sells tools for biomedical research based on nanotechnologies. Our products range from nanoparticles in suspensions to engineered surfaces for applications within stem cell research.
The company's lead product in development is Amorphous Nano-Hydroxyapaite Powder. Nano-structured hydroxyapatite has several advantages over hydroxyapatite of larger particle size in its use in bone tissue engineering due to its higher surface area and consequently higher reactivity, which offers better cellular response. In addition, nano-sized hydroxyapatite is useful as an effective surface modification agent for binding numerous biological molecules.
Mirexus Inc. is a natural biomaterials company that is commercializing a novel nanotechnology based on polysaccharide nanoparticles that can be used in a wide variety of markets ranging from cosmetics to nutraceuticals to biomedical applications in animal and human health. This technology was originally developed at the University of Guelph in the laboratories of Professor John Dutcher.